Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TMC Life Sciences Bhd's gross profit for the
three
months ended in Jun. 2026 was RM63.3 Mil. TMC Life Sciences Bhd's gross profit for the trailing twelve months (TTM) ended in Jun. 2026 was RM250.7 Mil.
TMC Life Sciences Bhd (XKLS:0101) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
TMC Life Sciences Bhd had a gross margin of 63.75% for the quarter that ended in Jun. 2026 => Durable competitive advantage
TMC Life Sciences Bhd Gross Profit Related Terms
TMC Life Sciences Bhd Gross Profit Historical Data
* Premium members only.
The historical data trend for TMC Life Sciences Bhd's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:0101 vs HCA, THC, EHC: Gross Profit Comparison
For the Medical Care Facilities subindustry, TMC Life Sciences Bhd's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TMC Life Sciences Bhd Gross Profit vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, TMC Life Sciences Bhd's Gross Profit distribution charts can be found below:
* The bar in red indicates where TMC Life Sciences Bhd's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was RM250.7 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
TMC Life Sciences Bhd (XKLS:0101) has a Gross Profit of RM250.7 Mil as of Jun. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on TMC Life Sciences Bhd and its competitors.
Is TMC Life Sciences Bhd's Gross Profit too high?
TMC Life Sciences Bhd's current Gross Profit is RM250.7 Mil. Overall, TMC Life Sciences Bhd has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TMC Life Sciences Bhd's Gross Profit compare to HCA and THC?
TMC Life Sciences Bhd's Gross Profit of RM250.7 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Healthcare Providers & Services company?
A good Gross Profit depends on the Healthcare Providers & Services industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on TMC Life Sciences Bhd and its competitors. TMC Life Sciences Bhd's current Gross Profit is RM250.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TMC Life Sciences Bhd stock overvalued right now?
Based on GuruFocus' analysis, TMC Life Sciences Bhd (XKLS:0101) is currently considered Modestly Undervalued. The stock's GF Value™ is RM0.58, compared to a current price of RM0.45 — trading 23.3% below its estimated fair value. The current Gross Profit is RM250.7 Mil. TMC Life Sciences Bhd's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For TMC Life Sciences Bhd (XKLS:0101), the current Gross Profit is RM250.7 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TMC Life Sciences Bhd (XKLS:0101) Overvalued in 2026?
Based on GuruFocus' analysis, TMC Life Sciences Bhd stock appears to be undervalued.
The current stock price of RM0.45 is trading 23.3% below its estimated GF Value™ of RM0.58.
GuruFocus considers TMC Life Sciences Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:0101:
Gross Profit: RM250.7 Mil
GF Value™: RM0.58 vs. price of RM0.45 (23.3% below fair value)
No single metric tells the full story. See the XKLS:0101 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TMC Life Sciences Bhd is an investment holding company operating a multi-disciplinary tertiary care center and fertility center in Malaysia. It operates Tropicana Medical Centre, Kota Damansara (TMCKD), a medical center located in Petaling Jaya. Its TMCKD provides healthcare services in various medical/surgical specialties and subspecialties, including anesthesiology, cancer, cardiology, colorectal, dermatology, ENT, fertility, gastroenterology, as well as offers internal medicines and respiratory medicines. Its fertility center provides a range of fertility treatments for couples. The company also operates a women's clinic; provides fertility consultancy, laboratory, and embryology services; and offers pharmacy services and products.
61GF Score
Get the complete analysis for XKLS:0101
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0101 has been successfully added to your 
